Factors influencing survival in metastatic synovial sarcoma: Importance of patterns of metastases and the first-line chemotherapy regimen

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Salah, Samer ^a   Yaser, Sameer ^a   Salem, Ahmed ^a   Mousa, Abdellatif Al ^a   Sheikha, Areej Abu ^a   Sultan, Iyad ^a  

^a KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

Antineoplastic agents; Neoplasm metastasis; Prognosis; Sarcoma; Synovial

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; EXTRA PULMONARY METASTASIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METASTASIS; METASTASIS RESECTION; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY METASTASECTOMY; SCHOOL CHILD; SYNOVIAL SARCOMA; YOUNG ADULT; DISEASE FREE SURVIVAL; MORTALITY; PATHOLOGY; PROGNOSIS; NEOPLASM METASTASIS; SARCOMA, SYNOVIAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SARCOMA, SYNOVIAL; YOUNG ADULT;

EID: 84878928705     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0639-z     Document Type: Article

References (26)

1. Siegel HJ, Sessions W, Casillas MA Jr, Said-Al-Naief N, Lander PH, Lopez-Ben R. Synovial sarcoma: clinicopathologic features, treatment, and prognosis. Orthopedics. 2007;30:1020-7.
2. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21:2719-25.
3. Ryan JR, Baker LH, Benjamin RS. The natural history of metastatic synovial sarcoma: experience of the Southwest Oncology group. Clin Orthop Relat Res. 1982;164:257-60.
4. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol. 2005;16(3):437-44.
5. Paulino AC. Synovial sarcoma prognostic factors and patterns of failure. Am J Clin Oncol. 2004;27(2):122-7.
6. Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer. 2009;115(13):2988-98.
7. Ferrari A, De Salvo GL, Dall'Igna P, et al. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. Eur J Cancer. 2012;48(18): 3448-55.
8. Buck P, Mickelson MR, Bonfiglio M. Synovial sarcoma: a review of 33 cases. Clin Orthop Relat Res. 1981;156:211-5.
9. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999;85:2596-607.
10. Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma: a clinicopathological study of 136 cases. Cancer. 1977;39 (3):1201-17.
11. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72-83.
12. Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer. 1997;80(7):1221-7.
13. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73(10):2506-11.
14. Przybyl J, Jurkowska M, Rutkowski P, Debiec-Rychter M, Siedlecki JA. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. Sarcoma. 2012;2012:249219. Doi:10.1155/2012/249219. Epub 2012 Mar 25.
15. Kekeeva TV, Riazantseva AA, Zavalishina LÉ, et al. Analysis of SYT/SSX1 and SYT/SSX2 fusion genes from synovial sarcoma. [Article in Russian]. Mol Biol (Mosk). 2011;45(5):840-4.
16. Srinivasan R, Gautam U, Gupta R, Rajwanshi A, Vasistha RK. Synovial sarcoma: diagnosis on fine-needle aspiration by morphology and molecular analysis. Cancer. 2009;117(2):128-36.
17. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol. 2008;97(4):314-20.
18. Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005;103(4):830-8.
19. Tawbi H, Thomas D, Lucas DR, et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist. 2008;13(4):459-66. doi:10.1634/theoncologist. 2007-0166.
20. Hosaka S, Horiuchi K, Yoda M, et al. A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3 K-AKT pathway. J Orthop Res. 2012;30(9):1493-8. Doi:10.1002/jor.22091. Epub 2012 Feb 22.
21. Peng CL, Guo W, Ji T, et al. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther. 2009; 8(18):1729-36.
22. Schöffski P. Pazopanib in the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther. 2012;12(6):711-23. doi:10.1586/era.12.41.
23. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126-32.
24. Deeks ED. Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012;72(16):2129-40.
25. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829): 1879-86.
26. Fukukawa C, Hanaoka H, Nagayama S, et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008;99(2):432-40.